iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
Boosted ABT-450/r HCV Protease 3-Day Monotherapy
  Ritonavir co-administration boosted the pharmacokinetics of ABT-450 with ABT-450 Cmax & AUC increased 28-fold & 48-fold: therefore, ABT-450 is being developed with low-dose RTV to enhance exposure & allow once-daily dosing. From day i through day 4, the mean maximum HCV RNA decreases from baseline was 4.02 log10 IU/mL for subjects receiving ABT-450/r.
Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects - (11/08/10)


  iconpaperstack View Older Articles   Back to Top   www.natap.org